Novo Nordisk shares fell sharply on Monday after the Wegovy maker set out its long-term targets at a capital markets day in London. Investors questioned whether the goals were enough to turn round a stock that has already lost more than 70 percent of its value since its peak.
The Danish drugmaker's shares dropped as much as 9 percent in Copenhagen before paring some of the fall; at 11:24 GMT they were 4.7 percent lower. The selling took the stock to its lowest level since April, according to Philip Jagd, head of equities at the pension fund Sampension.
The slide matters well beyond Denmark. The launch of Wegovy in 2021 pushed Novo's market value above $600 billion, making it one of Europe's best-known growth stories. Much of that valuation has since been eroded by competition, pricing pressure and weaker sales forecasts.
The targets Novo put to investors
Chief executive Mike Doustdar told investors the company aims to launch more than five blockbuster medicines by 2030, meaning products with net sales above $1 billion a year. It also targets more than 150 billion Danish crowns, about $23 billion, of sales in 2035 from products that have not yet launched.
That 2035 figure is built on internal, risk-adjusted pipeline assets and leaves out any future acquisitions. Novo also wants to widen its reach beyond obesity and diabetes, with medicines for liver and cardiovascular disease among the areas it named.
Novo's capital markets day in numbers
- 9% biggest intraday fall in the shares on Monday
- DKK 150bn+ pipeline sales targeted for 2035
- 60 million+ patients targeted by 2030
The company aims to reach more than 60 million patients worldwide by 2030. It plans to scale up manufacturing tenfold so it can supply 15 million patients with oral obesity treatments by the end of the decade, and wants at least five oral drug candidates in clinical trials by the end of this year.
Novo Nordisk: share price, chart and news

Why the market was unimpressed
Analysts focused on what the targets did not promise. The 2030 sales goal assumes only stable margins, which Markus Manns, a portfolio manager at Union Investment, described as "slightly underwhelming". He added that it was not a big surprise and that the guidance looked reasonable given biosimilar competition in Canada, Brazil and China and rival products from Amgen and Pfizer from 2028.
Pricing was the sharper concern. Semaglutide, the active ingredient in both Wegovy and Ozempic, loses patent protection in the early 2030s, and analysts questioned whether Novo's next-generation drugs can hold premium prices once cheaper versions of its current blockbuster are on the market.
Analysts and investors who spoke to the Danish business daily Børsen said the presentation lacked concrete goals and voiced concern about growth in the weight-loss market. In a written comment to the news agency Ritzau, Jagd said Novo's sales projections had worsened substantially over the past few years and that the company needed to show it can grow with the sector.
Lilly's lead in obesity drugs
The backdrop is a market Novo once dominated. Eli Lilly's Zepbound is on track to outsell Wegovy by more than $7 billion this year, according to LSEG data, a measure of how far the American rival has moved ahead.
The tablet is one bright spot. Doustdar said the oral version of Wegovy has reached a record 7 million US prescriptions to date, with about 90 percent of those sales going through direct cash-pay channels rather than insurers. That route gives Novo more direct contact with patients, but it also leaves sales more exposed to price-sensitive consumers.
The injectable pipeline is the next test:
| Medicine | Planned timing |
|---|---|
| CagriSema (combination) | Launch targeted for early next year |
| Cagrilintide alone and high-dose CagriSema | 2028 |
| Zenagamtide | After those launches; oral and injectable forms together |
Chief scientific officer Martin Holst Lange said the oral and injectable versions of zenagamtide would be launched at the same time rather than the injection first.
Room for bigger deals and a smaller workforce
Executives told investors the balance sheet can support larger acquisitions, not only small bolt-on deals. That opens the door to a bigger purchase to fill the gap left as semaglutide approaches the end of its exclusivity.
Novo has also been shrinking. Under a cost-cutting drive that began last year, staff departures have reached 13,000, the company disclosed on Monday, made up of an initial 9,000 job cuts and about 4,000 further exits since.
For shareholders, the message from Monday's trading is that targets alone will not restore confidence. The market wants evidence that Novo can grow with the obesity sector rather than lose share in it, and the next set of quarterly results will be read with that question in mind.








